ArticleVaccine2020
Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Crystal structure and nanobodies against domain 3 of the malaria parasite fusogen Plasmodium falciparum HAP2.The Biochemical journal · 2026Article
- Structural and antigenic characterization of Babesia Bovis HAP2 domains.Scientific reports · 2025Article
- Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.Immunological reviews · 2025Review
- Evaluation of the transmission-blocking potential ofFrontiers in cellular and infection microbiology · 2025Article
- Functional characterization of a conserved membrane protein, Pbs54, involved in gamete fertilization in Plasmodium berghei.International journal for parasitology · 2024Article
- Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase inFrontiers in cellular and infection microbiology · 2024Article
- A dual-antigen malaria vaccine targeting Pb22 and Pbg37 was able to induce robust transmission-blocking activity.Parasites & vectors · 2023Article
- A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax.NPJ vaccines · 2023Article
- Vaccination of cattle with the Babesia bovis sexual-stage protein HAP2 abrogates parasite transmission by Rhipicephalus microplus ticks.NPJ vaccines · 2023Article
- Article
- The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health.Viruses · 2022Review
- The transcriptome from asexual to sexual in vitro development of Cystoisospora suis (Apicomplexa: Coccidia).Scientific reports · 2022Article
- Transmission-Blocking Strategies Against Malaria Parasites During Their Mosquito Stages.Frontiers in cellular and infection microbiology · 2022Review
- Naturally acquired antibodies to gametocyte antigens are associated with reduced transmission ofFrontiers in cellular and infection microbiology · 2022Article
- Structural basis of malaria transmission blockade by a monoclonal antibody to gamete fusogen HAP2.eLife · 2021Article
- Molecular interactions between parasite and mosquito during midgut invasion as targets to block malaria transmission.NPJ vaccines · 2021Review
- Sexual Development in Non-Human Parasitic Apicomplexa: Just Biology or Targets for Control?Animals : an open access journal from MDPI · 2021Review
- Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.Parasites & vectors · 2021Article
- Identification of Novel Malaria Transmission-Blocking Vaccine Candidates.Frontiers in cellular and infection microbiology · 2021Review
- Historical Perspective and Biotechnological Trends to Block Arboviruses Transmission by ControllingFrontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Transmission-blocking vaccine (TBV) is a promising strategy to interfere with the transmission of malaria. To date, only limited TBV candidate antigens have been identified for Plasmodium vivax. HAP2 is a gamete membrane fusion protein, with homology to the class II viral fusion proteins. Herein we reported the characterization of the PvHAP2 for its potential as a TBV candidate for P. vivax. The HAP2/GCS1 domain of PvHAP2 was expressed in the baculovirus expression system and the recombinant protein was used to raise antibodies in rabbits. Indirect immunofluorescence assays showed that anti-PvHAP2 antibodies reacted only with the male gametocytes on blood smears. Direct membrane feeding assays were conducted using four field P. vivax isolates in Anopheles dirus. At a mean infection intensity of 72.4, 70.7, 51.3, and 15.6 oocysts/midgut with the control antibodies, anti-PvHAP2 antibodies significantly reduced the midgut oocyst intensity by 40.3, 44.4, 61.9, and 89.7%. Whereas the anti-PvHAP2 antibodies were not effective in reducing the infection prevalence at higher parasite exposure (51.3-72.4 oocysts/midgut in the control group), the anti-PvHAP2 antibodies reduced infection prevalence by 50% at a low challenge (15.6 oocysts/midgut). Multiple sequence alignment showed 100% identity among these Thai P. vivax isolates, suggesting that polymorphism may not be an impediment for the utilization of PvHAP2 as a TBV antigen. In conclusion, our results suggest that PvHAP2 could serve as a TBV candidate for P. vivax, and further optimization and evaluation are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.